Brompheniramine, loratadine, and placebo in allergic rhinitis: A placebo-controlled comparative clinical trial

Journal of Clinical Pharmacology

Volumn 38, Issue 4, 1998, Pages 382-389

  Druce, Howard M ^a   Thoden, William R ^a   Mure, Patti ^a   Furey, Sandy A ^a   Lockhart, Earle A ^a   Xie, Tailiang ^a   Galant, Stanley ^b   Prenner, Bruce M ^c   Weinstein, Steven ^d   Ziering, Robert ^e   Brandon, Milan L ^f  

^a PFIZER INC   (United States)

^b Clinical Trials of Orange County   (United States)

^c Allergy Associates Medical Group Inc   (United States)

^d Allerg Asthma Specialists Med Grp   (United States)

^e Allergy and Immunology Medical Group   (United States)

^f California Research Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BROMPHENIRAMINE; LORATADINE; PLACEBO;

ADOLESCENT; ADULT; AGED; ALLERGIC RHINITIS; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROTOXICITY; NOSE CONGESTION; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SNEEZING; SOMNOLENCE; SUSTAINED RELEASE PREPARATION; SYMPTOM;

EID: 0031949753     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04439.x     Document Type: Article

References (40)

1. Hardman JG, Limbird LE, Molinoff PB, Ruddon RW (eds.): Goodman and Gilman's The Pharmacological basis of Therapeutics. Ninth edition. New York: McGraw-Hill, 1996.
2. Simons FER: Antihistamines? In, Middleton E Jr, Reed CE, Ellis EF, Adkinson NF Jr, Yunginger JW, Busse WW (eds.): Allergy, Principles and Practice. Fourth edition. St. Louis: CV Mosby, 1993;856-892.
3. Reynolds JEF (ed.): Martindale: The Extra Pharmacopeia. Thirtieth edition. London: Pharmaceutical Press, 1993.
4. Aaronson DW: Comparative efficacy of antihistamines. Ann Allerg 1991;67:541-547.
5. MacLaren WR: Parabromdylamine maleate, chlorprophenpyridamine maleate, and tripelennamine hydrochloride in chronic allergic rhinitis. J Allerg 1959;30:235-240.
6. Schiller IW, Lowell FC: Further use of color coding in drug evaluations. N Engl J Med 1959;261:478-482.
7. Grater WC: Comparative effectiveness of two antihistamines in allergic rhinitis. Arch Otolaryngol 1960;72:63-65.
8. Mercke U, Wihl J: Clinical evaluation of an oral combined antihistaminic sympathomimetic preparation. Acta Allergol 1973; 28:108-117.
9. Mercke U, Wihl J: A controlled clinical comparison of Lunerin and Rinomar in allergic rhinitis. Acta Allergol 1973;28:118-125.
10. Kjellman NM: Treatment of children with perenial rhinitis with brompheniramine maleate and phenylpropanolamine hydrochloride (Lunerin Mite). Acta Allergol 1975;30:48-57.
11. Kapstad B, Warland A: Therapeutic effectiveness of an oral antihistamine combination (dexbrompheniramine maleate/d-isoephedrine sulphate) in the treatment of patients with allergic rhinitis. Acta Allergol 1976;31:223-226.
12. Blamoutier J: Comparative trial of two antihistamines, mequitazine and brompheniramine. Curr Med Res Opin 1978;5:366-370.
13. Georgitis JW, Shen D: Nasal pharmacodynamics of brompheniramine in perennial rhinitis. Arch Otolaryngol Head Neck Surg 1988;114:63-67.
14. Barenholtz HA, McLeod DC: Loratadine: a nonsedating antihistamine with once-daily dosing. Ann Pharmacother 1989;23: 445-450.
15. Koch GG, Carr GJ, Amara IA, Stokes ME, Uryniak TJ: Categorical data analysis. In, Berry DA (ed.): Statistical Methodology in the Pharmaceutical Sciences. New York: Marcel Dekker, 1990; 389-473.
16. Dockhorn RJ, Bergner A, Connell JT, Falliers CJ, Grabiec SV, Weiler JM, Shellenberger MK: Safety and efficacy of loratadine (Sch-29851): a new non-sedating antihistamine in seasonal allergic rhinitis. Ann Allerg 1987;58:407-411.
17. Kemp JP, Bahna SL, Chervinsky P, Rachelefsky GS, Seltzer JM, Nande Stouwe RA. Valero RN: A comparison of loratadine, a new non-sedating antihistamine, with clemastine and placebo in patients with fall season allergic rhinitis. Am J Rhinol 1987;1:151-154.
18. Skassa-Brociek W, Bouaquet J, Montes F, Verdier M, Schwab D, Lherminier M, Michel F-B: Double-blind placebo-controlled study of loratadine, mequatizine, and placebo in the symptomatic treatment of seasonal allergic rhinitis. J Allerg Clin Immunol 1988; 81:725-730.
19. Bruttman G, Pedrali P: Loratadine (SCH 29851) 40 mg once daily versus terfenadine 60 mg twice daily in the treatment of seasonal allergic rhinitis. J Int Med Res 1987;15:63-70.
20. del Carpio J, Kabbash L, Turenne Y, Prevost M, Hebert J, Bedard PM, et al: Efficacy and safety of loratadine (10 mg once daily), terfenadine (60 mg twice daily), and placebo in the treatment of seasonal allergic rhinitis. J Allerg Clin Immunol 1989;84: 741-746.
21. Gutkowski A, Bedard P, del Carpio J, Hebert J, Prevost M, Schulz J, et al: Comparison of the efficacy and safety of loratadine, terfenadine, and placebo in the treatment of seasonal allergic rhinitis. J Allerg Clin Immunol 1988;81:902-907.
22. Horak F, Bruttmann G, Pedrali P, Weeke B, Frolund L, Wolff HH, Christophers E: A multicentric study of loratadine, terfenadine and placebo in patients with seasonal allergic rhinitis. Arzneimittelforschung 1988;38:124-128.
23. Oei HD: Double-blind comparison of loratadine (SCH-29851), astemizole, and placebo in hay fever with special regard to onset of action. Ann Allerg 1988;61:436-439.
24. Frølund L, Etholm B, Irander K, Johannessen TA, Ödkvist L, Ohlander B, Weeke B: A multicentre study of loratadine, clemastine and placebo in patients with perennial allergic rhinitis. Allergy 1990;45:254-261.
25. Meltzer EO, Weiler JM, Widlitz MD: Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine and placebo for seasonal allergic rhinitis. J Allerg Clin Immunol 1996;97:617-626.
26. Lockey RF, Widlitz MD, Mitchell DQ, Lumry W, Dockhorn R, Woehler T, Grossman J: Comparative study of cetirizine and terfenadine versus placebo in the symptomatic management of seasonal allergic rhinitis. Ann Allerg Asthma Immunol 1996;76:448-454.
27. Klein GL, Littlejohn III T, Lockhart EA, Furey SA: Brompheniramine, terfenadine, and placebo in allergic rhinitis. Ann Allerg Asthma Immunol 1996;77:365-370.
28. Simons FER, McMillan JL, Simons KJ: A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 hours in normal patients. J Allerg Clin Immunol 1990;86:540-547.
29. Rosenzweig P, Caplain H, Chaufour S, Ulliac N, Cabanis MJ, Thebault JJ: Comparative wheal and flare study of mizolastine vs terfenadine, cetirizine, loratadine and placebo in healthy volunteers. Br J Pharmacol 1995;40:459-465.
30. Simons FER: The eternal triangle: benefit, risk, and cost of therapeutic agents (editorial). Ann Allerg 1996;77:337-340.
31. Bye, Claridge R, Peck AW, Plowman F: Evidence for tolerance to the central nervous system effects of the histamine antagonist, tripolidine, in man. Eur J Clin Pharmacol 1977;12:181-186.
32. Nicholson AN: Effects of the antihistamines, brompheniramine maleate and tripolidine hydrochloride, on performance in man. Br J Clin Pharmacol 1979;8:321-324.
33. Seppala T, Nuotto E, Korttila K: Single and repeated dose comparison of three antihistamines and phenylpropanolamine: psychomotor performance and subjective appraisals of sleep. Br J Clin Pharmacol 1981;12:179-188.
34. Manning C, Scandale L, Manning MD, Gengo FM: Central nervous system effects of meclizine and dimenhydrinate: evidence of acute tolerance to antihistamines. J Clin Pharmacol 1992; 32:996-1002.
35. Schweitzer PK, Muehlback MJ, Walsh JK: Sleepiness and performance during three-day administration of cetirizine or diphenhydramine. J Allerg Clin Immunol 1994;94:716-724.
36. Goetz DW, Jacobson JM, Murnane IE, Reid MJ, Repperger DW, Goodyear C, Martin ME: Prolongation of simple and choice reaction times in a double-blind comparison of twice-daily hydroxyzine versus terfenadine. J Allerg Clin Immunol 1989;84: 316-322.
37. 1-histamine receptor antagonist ebastine in 10, 20, and 30 mg dose, and tripolidine 10 mg in car driving performance. Br J Clin Pharmacol 1993;36:67-70.
38. 1-receptor antagonists: comparative tolerability and safety. Drug Safety 1994;10:350-380.
39. 1-receptor antagonists). Ann Allerg Asthma Immunol 1995;75: 507-514.
40. Gwaltney JM Jr, Druce HM: Efficacy of brompheniramine for rhinovirus colds. Clin Infect Dis (in press).